SCHEMBL4704243

SCHEMBL4704243

COc1ccc2c(Cc3c(Cl)cncc3Cl)nnc(-c3sccc3C(=O)O)c2c1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 20/20 0.67
PDE4B Q07343 20/20 0.67
PDE4C Q08493 20/20 0.67
PDE4D Q08499 20/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4704587 0.87 PDE4A (0.65) PDE4APDE4BPDE4CPDE4D
SCHEMBL4704462 0.84 PDE4A (0.68) PDE4APDE4BPDE4CPDE4D
SCHEMBL4699329 0.83 PDE4A (0.71) PDE4APDE4BPDE4CPDE4D
SCHEMBL4699266 0.81 PDE4D (0.69) PDE4APDE4BPDE4CPDE4D
SCHEMBL4701819 0.81 PDE4A (0.77) PDE4APDE4BPDE4CPDE4D
SCHEMBL6589533 0.81 PDE4A (1.00) PDE4APDE4BPDE4CPDE4D
SCHEMBL4699913 0.80 PDE4A (0.66) PDE4APDE4BPDE4CPDE4D
SCHEMBL4702281 0.80 PDE4A (0.63) PDE4APDE4BPDE4CPDE4D
SCHEMBL4701597 0.79 PDE4A (0.71) PDE4APDE4BPDE4CPDE4D
SCHEMBL4699816 0.79 PDE4A (0.76) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581229-B1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2008-03-12 EP claimed
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2006-07-27 US claimed
EP-1581229-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2005-10-05 EP claimed
WO-2004056366-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2004-07-08 WO claimed
EP-1581229-B1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2008-03-12 EP disclosed
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2006-07-27 US disclosed
EP-1581229-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2005-10-05 EP disclosed
WO-2004056366-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166996-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors PDE4A, PDE5A, PDE2A PDE4A 1/4885PDE4B 6/4885PDE4C 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.